GRAIL (NASDAQ: GRAL) plans 2025 update at J.P. Morgan healthcare event

Rhea-AI Filing Summary

GRAIL, Inc. reported that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. The presentation used for this event is being made available as Exhibit 99.1 to this report.

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished rather than filed under the securities laws, meaning it is not automatically subject to certain liability provisions or incorporated into other regulatory filings unless specifically referenced.

0001699031FALSE00016990312026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

_____________________________________________

GRAIL, Inc.

(Exact Name of Registrant as Specified in Charter)

___________________________________________

Delaware			001-42045			86-3673636
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1525 O’Brien Drive Menlo Park, California 94025

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (833) 694-2553

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

GRAL

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of operations and financial condition.

On January 12, 2026, GRAIL, Inc. (the “Company”) plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. A copy of the presentation that will be used is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto are intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall be expressly set forth by specific reference in such filing, the information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01    Exhibits.

(d) Exhibits.

99.1* Results of operations and financial condition.

____________

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GRAIL, INC.

Date:

January 12, 2026

By:

/s/ Aaron Freidin

Name:

Aaron Freidin

Title:

Chief Financial Officer

FAQ

What did GRAIL (GRAL) disclose in this 8-K filing?

GRAIL, Inc. disclosed that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference, with the related presentation furnished as Exhibit 99.1.

What time period does GRAIL’s preliminary financial information cover?

The preliminary financial information GRAIL plans to present covers both the quarter and the full year ended December 31, 2025.

Where can investors find the presentation GRAIL will use at the 2026 J.P. Morgan Healthcare Conference?

The presentation GRAIL plans to use at the 2026 J.P. Morgan Healthcare Conference is furnished as Exhibit 99.1 to this report.

Is GRAIL’s conference presentation considered filed with the SEC?

No. GRAIL states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Will GRAIL’s Exhibit 99.1 be incorporated into other SEC filings automatically?

GRAIL notes that the information in this report and Exhibit 99.1 will not be incorporated by reference into other SEC filings unless expressly set forth by specific reference in those filings.

Who signed this GRAIL (GRAL) current report on Form 8-K?

The report was signed on behalf of GRAIL, Inc. by Aaron Freidin, the company’s Chief Financial Officer.